Evidence map›Paper›PMID 39846292›Full record

ArticleThe Journal of pathology2025

Alternative driver pathways in peripheral nerve sheath tumors - including DICER1 and/or KRAS alterations.

Hsin-Yi Chang, Carla Saoud, Dianne Torrence, William Tap, Ping Chi, Cristina R Antonescu

Abstract readCase Reports
In one paragraph

Article in The Journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hsin-Yi ChangDepartment of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.ORCID 0009-0008-8121-8322
Carla SaoudDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Dianne TorrenceDepartment of Pathology, Northwell Health, New York, NY, USA.
William TapDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ping ChiDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cristina R AntonescuDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Targeting Oncogenic Pathways in Genetically Complex SarcomasP50CA217694 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Marc Ladanyi · 2018 to 2026
$21.5M
Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST)U01CA252048 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHI, PING · 2021 to 2025
$3.1M
Harnessing double stranded-RNA (dsRNA)-response and anti-tumor effect in PRC2-inactivated cancerR01CA280657 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Ping Chi · 2023 to 2026
$2.9M
Cycle for SurvivalKristin Ann Carr FoundationMarie-Josée and Henry R. Kravis Center for Molecular OncologyNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA217694NCI NIH HHS R01 CA280657NCI NIH HHS U01 CA252048NIH HHS P30 CA008748NIH HHS P50 CA217694
6 · The paper itself

Abstract

DICER1-associated sarcoma is an emerging entity, defined by either somatic or germline dicer 1, ribonuclease III (DICER1) mutations and sharing characteristic morphologic features irrespective of the site of origin. In addition to the DICER1 driver mutation, concurrent genomic alterations, including tumor protein 53 (TP53) inactivation and RAS pathway activation, are frequently detected. Tumors that morphologically resemble malignant peripheral nerve sheath tumor (MPNST) have rarely been reported among DICER1 sarcomas and often pose diagnostic challenges. This study was prompted by a case involving morphologic features of MPNST, which harbored co-existing DICER1 and hotspot KRAS mutations. Hence, we investigated the incidence of these alterations in PNST from our molecular database compared to the genomic and morphologic spectrum of DICER1-mutant sarcomas. In total, we identified three cases diagnosed as MPNST with co-existing DICER1, ATRX chromatin remodeler (ATRX), and KRAS G12V/A alterations occurring in brain, cerebellopontine angle, and intra-abdominal sites. Two additional cases each of MPNSTs and neurofibromas were identified with hotspot KRAS mutations. All five MPNSTs lacked canonical neurofibromin 1 (NF1)/neurofibromin 2 (NF2) alterations, displaying a classic morphologic appearance with fascicular monomorphic spindle cells and followed a diverse clinical behavior. Among the 38 DICER1-associated sarcomas in our database, eight (21%) had secondary KRAS hotspot mutations, all composed of monomorphic spindle and/or round cells, including three with an MPNST-like histology. In contrast, all 10 (26%) DICER1-mutant sarcomas with TP53 mutations showed a pleomorphic phenotype. The DNA-based methylation profile of our index case clustered within the group of sarcomas with DICER1 alterations. Our results highlight a small subset of MPNST associated with DICER1 and/or KRAS mutations. However, their relationship with conventional MPNST remains to be determined in larger studies. © 2025 The Pathological Society of Great Britain and Ireland.

Indexed as

Biomarkers, TumorDEAD-box RNA HelicasesMutationNerve Sheath NeoplasmsProto-Oncogene Proteins p21(ras)Ribonuclease IIIAdultAgedFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedSignal TransductionBiomarkers, TumorDEAD-box RNA HelicasesDICER1 protein, humanKRAS protein, humanProto-Oncogene Proteins p21(ras)Ribonuclease IIIATRXDICER1KRASmethylationMPNSTperipheral nerve sheath tumorTP53

Identifiers

PMID39846292
PMCPMC12247263

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.